Skip to main content

Angiodynamics Value Stock - Dividend - Research Selection

Angiodynamics

ISIN: US03475V1017 , WKN: A0B9A5

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield%
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



DescriptionData
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

AngioDynamics, Inc. designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities. It also offers AngioVac venous drainage system that includes venous drainage cannula for the removal of fresh, soft thrombi, or emboli during extracorporeal bypass; and cardiopulmonary bypass circuit for use in procedures during extracorporeal circulatory support. In addition, the company provides thrombolytic catheters to deliver thrombolytic agents; angiographic products and accessories for use in during peripheral vascular interventional procedures; drainage products, which drain abscesses and other fluid pockets; and micro access sets. Further, it offers peripherally inserted central catheters; ports that are implantable devices for the central venous administration; and dialysis products. Additionally, the company provides microwave ablation products; radiofrequency ablation products for ablating solid cancerous or benign tumors; and NanoKnife ablation systems for the surgical ablation of soft tissues. It sells and markets its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly, as well as through distributor relationships. The company was founded in 1988 and is headquartered in Latham, New York.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


AngioDynamics (ANGO) Loses -15.86% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner

2024-10-08
AngioDynamics (ANGO) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.

Insider Buying: President and CEO James Clemmer Acquires Shares of AngioDynamics Inc (ANGO)

2024-10-08
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

AngioDynamics Stock Up on Q1 Earnings Beat, Y/Y Pro-Forma Sales Rise

2024-10-04
AngioDynamics (ANGO) delivers decent top-line results on a pro-forma basis in first-quarter fiscal 2025, driven by strength in the Med Tech business.

AngioDynamics Sees Growth Amidst Challenges in Fiscal 2025

2024-10-04
AngioDynamics ( (ANGO) ) has shared an announcement. AngioDynamics announced a promising start to fiscal year 2025 with a slight increase in overall net sales and significant growth in its Med Tech segment, driven by Auryon and AlphaVac products. The company reported a GAAP net loss but a reduced adjusted net loss per share compared to the previous year and has provided an optimistic outlook with expected growth in both Med Tech and Med Device net sales. Despite the challenges of inflationary pr

4 Analysts Assess AngioDynamics: What You Need To Know

2024-10-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

AngioDynamics (ANGO) Gets a Buy from H.C. Wainwright

2024-10-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Q1 2025 AngioDynamics Inc Earnings Call

2024-10-04
Q1 2025 AngioDynamics Inc Earnings Call

AngioDynamics Inc (ANGO) Q1 2025 Earnings Call Transcript Highlights: A Promising Start with ...

2024-10-04
Despite challenges, AngioDynamics Inc (ANGO) shows progress towards profitability and strategic market expansion in its first quarter of fiscal 2025.

Wall Street Analysts Are Bullish on Top Healthcare Picks

2024-10-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

AngioDynamics price target lowered by $1 at Canaccord, here's why

2024-10-04
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.